<DOC>
	<DOCNO>NCT00609739</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug , cytarabine mitoxantrone , donor stem cell transplant help stop growth cancer cell help stop patient 's immune system reject donor 's stem cell . When certain stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine , methotrexate , methylprednisolone transplant may stop happen . PURPOSE : This phase I/II trial study side effect best way give high-dose cytarabine together mitoxantrone treat patient juvenile myelomonocytic leukemia undergo second donor stem cell transplant .</brief_summary>
	<brief_title>Cytosine Arabinoside Mitoxantrone Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine incidence 1-year disease-free survival patient juvenile myelomonocytic leukemia undergo repeat stem cell transplantation . Secondary - To evaluate incidence regimen-related toxicity . - To evaluate incidence acute chronic graft-versus-host-disease . - To evaluate incidence relapse . OUTLINE : - Preparative cytoreductive therapy : Patients receive high-dose cytarabine IV 2 hour day -9 -4 mitoxantrone hydrochloride IV 30 minute day -9 -7 . - Allogeneic hematopoietic stem cell transplantation ( HSCT ) : Patients undergo HSCT day 0 . Patients undergo umbilical cord blood transplantation receive methylprednisolone ( graft failure prophylaxis ) IV twice daily day 5 19 follow taper every day thereafter day 25 . - Graft-versus-host-disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV 2 hour every 8-12 hour orally twice daily begin day -3 continue day 50 , follow taper day 90 , absence GVHD . Patients undergo nongenotypically identical bone marrow transplantation also receive methotrexate IV day 1 begin 24 hour completion stem cell infusion day 3 , 6 , 11 . - Post-transplantation isotretinoin therapy : Patients receive oral isotretinoin daily begin day 60 continue 1 year HSCT . Patients undergo bone marrow sample collection day 21 , day 60 , day 100 , 6 month , 1 year chimerism study . Patients also undergo blood sample collection periodically monitor peripheral blood count immune reconstitution . After completion study treatment , patient follow day 21 , day 100 , 6 month , 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients age 018 juvenile myelomonocytic leukemia ( JMML ) relapse residual disease allogeneic HCT . Residual disease define failure eradicate original disease without prior documentation remission . Relapse define reappearance ) leukocytosis absolute monocytosis &gt; 1 x 10^8/L , ii ) presence immature myeloid cell peripheral circulation two consecutive bone marrow specimens take least one month apart , iii ) presence clonal cytogenetic abnormality . The diagnosis relapse support return abnormal cytogenetic marker ( present diagnosis ) presence host cell RFLP method . Patients least 6 month first hematopoietic cell transplant ( HCT ) clinically stable . ( If JMML rapidly progressive , second HCT may perform early ) . Adequate major organ function include : Cardiac : ejection fraction ≥45 % Pulmonary : FEV &gt; 50 % , DLCO &gt; 50 % Renal : creatinine clearance ≥40 mL/min Hepatic : clinical evidence hepatic failure ( e.g . coagulopathy , ascites ) Karnofsky performance status ≥70 % Lansky score ≥50 % Written informed consent . Active uncontrolled infection within one week HCT .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>juvenile myelomonocytic leukemia</keyword>
</DOC>